Sionna Therapeutics Q2 net loss $18.1M; positive Phase 1 data for NBD1 stabilizers

Sionna Therapeutics, Inc.

2025-Q2 EPS reported -$980.00 vs consensus -$0.57 ▼ miss (-173014.3%)

Net loss $18.1M in Q2 2025 vs $8.6M in Q2 2024; R&D expenses $15.4M.
Cash and equivalents $337.3M as of June 30, 2025; funding expected into 2028.
Positive Phase 1 data for SION-719 and SION-451: well tolerated, exceeded PK targets.
Phase 2a trial of SION-719 as add-on to CF standard of care on track for H2 2025; topline data mid-2026.
Phase 1 dual combination trial of SION-451 with galicaftor and SION-109 on track for H2 2025; data mid-2026.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.